Expression of a Down-Regulated Target, Ssecks, Reverses V-Jun-Induced Transformation of 10T1/2 Murine ®Broblasts

Total Page:16

File Type:pdf, Size:1020Kb

Expression of a Down-Regulated Target, Ssecks, Reverses V-Jun-Induced Transformation of 10T1/2 Murine ®Broblasts Oncogene (2001) 20, 141 ± 146 ã 2001 Nature Publishing Group All rights reserved 0950 ± 9232/01 $15.00 www.nature.com/onc ORIGINAL PAPERS Expression of a down-regulated target, SSeCKS, reverses v-Jun-induced transformation of 10T1/2 murine ®broblasts Steven B Cohen1, Anke Waha2, Iwin H Gelman3 and Peter K Vogt*,2 1Gen-Probe Incorporated, 10210 Genetic Center Drive, San Diego, California CA 92121, USA; 2Department of Molecular and Experimental Medicine, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California CA 92037, USA; 3Department of Microbiology, Mount Sinai School of Medicine, New York, NY 10029-6574, USA Line 10T1/2 mouse ®broblast overexpressing the v-Jun its cellular counterpart by a 27-amino acid deletion and oncoprotein were morphologically altered, grew into by two amino acid substitutions (Nishimura and Vogt, multilayered foci in culture and formed colonies when 1988). These mutations synergize to make Jun suspended in agar. The growth rate of the v-Jun- independent of cellular regulation and to turn it into transformed 10T1/2 cells was not changed signi®cantly a strong growth promoter (Abate et al., 1990; Boyle et from that of the untransformed parental cells, but the al., 1991; Chida and Vogt, 1992; Hibi et al., 1993; saturation density of the transformed cultures exceeded Morgan et al., 1993; 1994). that of normal controls by a factor of 2. mRNA v-Jun induces oncogenic transformation by aberrant extracted from v-Jun-transformed 10T1/2 cells was regulation of speci®c target genes. The dierential analysed for dierential gene expression with DNA expression of these targets determines the neoplastic micro-array technology. One of the targets downregu- phenotype of the cell. An understanding of transforma- lated by v-Jun was identi®ed as SSeCKS (Src-suppressed tion requires the identi®cation and characterization of C kinase substrate). Re-expression of SSeCKS in v-Jun- these targets. Previous work has revealed several genes transformed ®broblasts reversed the transformed pheno- that are up-regulated in v-Jun-transformed avian cells type of the cells. Their ability to form foci was reduced including bkj (Hartl and Bister, 1995), jtab (Hadman et to background levels, the number and size of agar al., 1996), glutaredoxin (Goller et al., 1998), hbegf (Fu colonies was lowered by a factor of 10 and the saturation et al., 1999) and ril (Fu et al., 2000). These genes were density was signi®cantly diminished. However, expres- identi®ed by various forms of substractive hybridiza- sion of SSeCKS had little eect on the morphology of v- tion which typically cover only a small fraction of the Jun-transformed 10T1/2 cells. These data suggest that transcriptome. More comprehensive expression pro®l- the SSeCKS protein has growth-attenuating properties. ing is provided by DNA micro-arrays, which are not Down-regulation of SSeCKS may be essential for Jun- yet available for avian genomes. Therefore, we induced transformation. Oncogene (2001) 20, 141±146. established a murine transformation system for Jun. Primary rodent cells are refractory to Jun transforma- Keywords: oncogenic transformation; dierential gene tion, but some continuous mammalian cell lines are expression: DNA micro-array; tumor suppressor susceptible to the growth-promoting eects of Jun (Schutte et al., 1989). We chose murine 10T1/2 cells to generate materials for DNA micro-array analysis. Introduction 10T1/2 cells were stably transformed with a retroviral vector expressing v-Jun. They became refractile, grew The transcription factor Jun belongs to the basic into multi-layered foci at high population densities and region/leucine zipper (bZip) protein family. Jun formed colonies when suspended in nutrient agar. dimerizes with itself or with other bZip proteins to mRNA from these v-Jun-transformed cells and from form the AP-1 transcription factor complex which their normal 10T1/2 progenitors was used to identify recognizes the DNA target sequence TGACTCA (TRE up- and down-regulated genes in commercial DNA sequence) and controls gene expression. Jun can induce micro-arrays (Incyte Pharmaceuticals). This commu- oncogenic transformation; this activity requires the nication will characterize one of the down-regulated three basic functions of the protein: dimerization, genes, SSeCKS (Src suppressed C kinase substrate). DNA binding and transcriptional regulation (Morgan This myristylated protein is rapidly translocated from et al., 1992). An oncogenic version of Jun is transduced the cortical cytoskeletal matrix to the perinucleus in by the avian retrovirus ASV17 and is referred to as v- response to treatment with phorbol esters (Lin et al., Jun (Bos et al., 1990; Maki et al., 1987). It diers from 1996). SSeCKS is down-regulated in rodent ®broblasts transformed by Src, Ras, Fos or Myc but shows unchanged levels of expression in cells transformed by Raf, Mos or Neu (Lin et al., 1995). SSeCKS expression *Correspondence: PK Vogt Received 7 August 2000; revised 25 October 2000; accepted 1 has also been found to be down-regulated in human November 2000 breast cancer cell lines as compared to normal breast V-Jun down regulated SSeCKS in murine fibroblasts SB Cohen et al 142 epithelial cells (Zhang et al., 1995). Expression of Jun-expressing cells were round and refractile, ap- SSeCKS in Src-transformed NIH3T3 cells has the peared less adherent and grew in an irregular pattern. eect of attenuating the transformed phenotype (Lin and Gelman, 1997). In the current study, expression of v-Jun expressing 10T1/2 cells lose contact inhibition of SSeCKS in v-Jun-transformed 10T1/2 cells induced a growth and gain the ability to form colonies of agar dramatic reduction of their oncogenic growth proper- ties. These observations suggest that SSeCKS can 10T1/2 cells transformed by Jun multiplied initially at function as a tumor suppressor. the same rate as control cells but they reached a far higher saturation density (Figure 2), forming sheets of multiple cell layers which have lost contact inhibition of growth. Focus formation on plastic support was Results assayed by plating various dilutions of v-Jun-trans- formed 10T1/2 cells together with a constant number Expression of v-Jun in 10T1/2 cells causes morphological of vector-transfected controls (Brugarolas et al., 1998). transformation Highly ecient focus formation was observed with v- v-Jun is a highly eective oncogene for chicken embryo Jun-expressing 10T1/2 cells; vector controls produced ®broblasts (CEF), inducing morphological transforma- only a low background number of foci (Figure 3). tion and robust anchorage-independent growth (Bos et In order to examine anchorage-independent growth, al., 1990; Maki et al., 1987). In primary mammalian v-Jun-expressing cells were suspended in 0.35% cell cultures expressing v-Jun, such transformation is nutrient agar. The number of colonies was determined not observed, but continuous rodent cell lines are after 4 weeks (Table 1 and Figure 4). Vector-infected susceptible to transformation (Schutte et al., 1989). In cells did not grow in suspension, while v-Jun- a comparison of several murine cell lines, 10T1/2 cells transformed 10T1/2 cells produced colonies with an emerged as most sensitive to v-Jun-induced transforma- eciency of greater than 30%. tion and were therefore chosen for expression-pro®ling using commercially available DNA micro-array tech- SSeCKS expression is repressed in v-Jun-transformed nology. For virus production, the chicken v-Jun cDNA 10T1/2 cells without Gag sequences (VJ1), was subcloned into the pBabe-puro vector and transfected into the BOSC23 The identi®cation of genes with altered expression ecotropic packaging cell line. The replication-defective patterns is critical to an understanding of oncogenic infectious viruses were then used to infect the transformation. Expression-pro®ling was therefore amphotropic PA317 packaging cell line, and virus performed with the v-Jun-transformed 10T1/2 cells. producers were selected with puromycin. Harvests from Four individual agar colonies were picked, expanded these cells were used to infect 10T1/2 cells, inducing a and used to generate poly(A)+ RNA. DNA micro- characteristic morphological transformation (Figure 1). arrays identi®ed 221 genes that are dierentially Compared to controls infected with empty vector, v- expressed by a factor of greater than two in v-Jun- transformed cells; 147 were up-regulated, and 74 were down-regulated. Initial attention focused on the down- regulated genes, because the signi®cance of the down- regulation for transformation can be readily tested by reexpressing the gene in question. A partial listing of Figure 2 v-Jun-transformation of 10T1/2 cells leads to increased Figure 1 v-Jun-infection of 10T1/2 cells causes morphological saturation density that is attenuated by SSeCKS expression. transformation. 10T1/2 cells were infected with either p-Babe- 10T1/2 cells were infected with p-Babe-hygro-SSeCKS and VJ1 puro or p-Babe-puro-VJ1 virus and then selected with puromycin 10T1/2 cells were super-infected with SSeCKS as described in as described in Materials and methods. Cells were allowed to Materials and methods. Cells were plated at 26104 cells in grow to con¯uency and photographed at 1006magni®cation with 35 mm plates, and counted every day for 9 days. The experiment phase contrast optics was run three times, and a representative example is shown Oncogene V-Jun down regulated SSeCKS in murine fibroblasts SB Cohen et al 143 Figure 4 v-Jun-expression in 10T1/2 cells leads to anchorage- independent growth that is attenuated by SSeCKS expression. The cells used were the same as described in Figures 1 and 2. 1.256104 cells were suspended in 2 ml of 0.35% nutrient agar in 60 mm plates that contained 3 ml of pre-cast 0.7% agar. Cells were fed every 5 days, and after 4 weeks were photographed.
Recommended publications
  • The Retinoblastoma Tumor-Suppressor Gene, the Exception That Proves the Rule
    Oncogene (2006) 25, 5233–5243 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc REVIEW The retinoblastoma tumor-suppressor gene, the exception that proves the rule DW Goodrich Department of Pharmacology & Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA The retinoblastoma tumor-suppressor gene (Rb1)is transmission of one mutationally inactivated Rb1 allele centrally important in cancer research. Mutational and loss of the remaining wild-type allele in somatic inactivation of Rb1 causes the pediatric cancer retino- retinal cells. Hence hereditary retinoblastoma typically blastoma, while deregulation ofthe pathway in which it has an earlier onset and a greater number of tumor foci functions is common in most types of human cancer. The than sporadic retinoblastoma where both Rb1 alleles Rb1-encoded protein (pRb) is well known as a general cell must be inactivated in somatic retinal cells. To this day, cycle regulator, and this activity is critical for pRb- Rb1 remains an exception among cancer-associated mediated tumor suppression. The main focus of this genes in that its mutation is apparently both necessary review, however, is on more recent evidence demonstrating and sufficient, or at least rate limiting, for the genesis of the existence ofadditional, cell type-specific pRb func- a human cancer. The simple genetics of retinoblastoma tions in cellular differentiation and survival. These has spawned the hope that a complete molecular additional functions are relevant to carcinogenesis sug- understanding of the Rb1-encoded protein (pRb) would gesting that the net effect of Rb1 loss on the behavior of lead to deeper insight into the processes of neoplastic resulting tumors is highly dependent on biological context.
    [Show full text]
  • DNA Microarrays (Gene Chips) and Cancer
    DNA Microarrays (Gene Chips) and Cancer Cancer Education Project University of Rochester DNA Microarrays (Gene Chips) and Cancer http://www.biosci.utexas.edu/graduate/plantbio/images/spot/microarray.jpg http://www.affymetrix.com Part 1 Gene Expression and Cancer Nucleus Proteins DNA RNA Cell membrane All your cells have the same DNA Sperm Embryo Egg Fertilized Egg - Zygote How do cells that have the same DNA (genes) end up having different structures and functions? DNA in the nucleus Genes Different genes are turned on in different cells. DIFFERENTIAL GENE EXPRESSION GENE EXPRESSION (Genes are “on”) Transcription Translation DNA mRNA protein cell structure (Gene) and function Converts the DNA (gene) code into cell structure and function Differential Gene Expression Different genes Different genes are turned on in different cells make different mRNA’s Differential Gene Expression Different genes are turned Different genes Different mRNA’s on in different cells make different mRNA’s make different Proteins An example of differential gene expression White blood cell Stem Cell Platelet Red blood cell Bone marrow stem cells differentiate into specialized blood cells because different genes are expressed during development. Normal Differential Gene Expression Genes mRNA mRNA Expression of different genes results in the cell developing into a red blood cell or a white blood cell Cancer and Differential Gene Expression mRNA Genes But some times….. Mutations can lead to CANCER CELL some genes being Abnormal gene expression more or less may result
    [Show full text]
  • P14ARF Inhibits Human Glioblastoma–Induced Angiogenesis by Upregulating the Expression of TIMP3
    P14ARF inhibits human glioblastoma–induced angiogenesis by upregulating the expression of TIMP3 Abdessamad Zerrouqi, … , Daniel J. Brat, Erwin G. Van Meir J Clin Invest. 2012;122(4):1283-1295. https://doi.org/10.1172/JCI38596. Research Article Oncology Malignant gliomas are the most common and the most lethal primary brain tumors in adults. Among malignant gliomas, 60%–80% show loss of P14ARF tumor suppressor activity due to somatic alterations of the INK4A/ARF genetic locus. The tumor suppressor activity of P14ARF is in part a result of its ability to prevent the degradation of P53 by binding to and sequestering HDM2. However, the subsequent finding of P14ARF loss in conjunction with TP53 gene loss in some tumors suggests the protein may have other P53-independent tumor suppressor functions. Here, we report what we believe to be a novel tumor suppressor function for P14ARF as an inhibitor of tumor-induced angiogenesis. We found that P14ARF mediates antiangiogenic effects by upregulating expression of tissue inhibitor of metalloproteinase–3 (TIMP3) in a P53-independent fashion. Mechanistically, this regulation occurred at the gene transcription level and was controlled by HDM2-SP1 interplay, where P14ARF relieved a dominant negative interaction of HDM2 with SP1. P14ARF-induced expression of TIMP3 inhibited endothelial cell migration and vessel formation in response to angiogenic stimuli produced by cancer cells. The discovery of this angiogenesis regulatory pathway may provide new insights into P53-independent P14ARF tumor-suppressive mechanisms that have implications for the development of novel therapies directed at tumors and other diseases characterized by vascular pathology. Find the latest version: https://jci.me/38596/pdf Research article P14ARF inhibits human glioblastoma–induced angiogenesis by upregulating the expression of TIMP3 Abdessamad Zerrouqi,1 Beata Pyrzynska,1,2 Maria Febbraio,3 Daniel J.
    [Show full text]
  • Review Article PTEN Gene: a Model for Genetic Diseases in Dermatology
    The Scientific World Journal Volume 2012, Article ID 252457, 8 pages The cientificWorldJOURNAL doi:10.1100/2012/252457 Review Article PTEN Gene: A Model for Genetic Diseases in Dermatology Corrado Romano1 and Carmelo Schepis2 1 Unit of Pediatrics and Medical Genetics, I.R.C.C.S. Associazione Oasi Maria Santissima, 94018 Troina, Italy 2 Unit of Dermatology, I.R.C.C.S. Associazione Oasi Maria Santissima, 94018 Troina, Italy Correspondence should be addressed to Carmelo Schepis, [email protected] Received 19 October 2011; Accepted 4 January 2012 Academic Editors: G. Vecchio and H. Zitzelsberger Copyright © 2012 C. Romano and C. Schepis. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. PTEN gene is considered one of the most mutated tumor suppressor genes in human cancer, and it’s likely to become the first one in the near future. Since 1997, its involvement in tumor suppression has smoothly increased, up to the current importance. Germline mutations of PTEN cause the PTEN hamartoma tumor syndrome (PHTS), which include the past-called Cowden, Bannayan- Riley-Ruvalcaba, Proteus, Proteus-like, and Lhermitte-Duclos syndromes. Somatic mutations of PTEN have been observed in glioblastoma, prostate cancer, and brest cancer cell lines, quoting only the first tissues where the involvement has been proven. The negative regulation of cell interactions with the extracellular matrix could be the way PTEN phosphatase acts as a tumor suppressor. PTEN gene plays an essential role in human development. A recent model sees PTEN function as a stepwise gradation, which can be impaired not only by heterozygous mutations and homozygous losses, but also by other molecular mechanisms, such as transcriptional regression, epigenetic silencing, regulation by microRNAs, posttranslational modification, and aberrant localization.
    [Show full text]
  • Wnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response
    International Journal of Molecular Sciences Review Wnt-Independent and Wnt-Dependent Effects of APC Loss on the Chemotherapeutic Response Casey D. Stefanski 1,2 and Jenifer R. Prosperi 1,2,3,* 1 Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46617, USA; [email protected] 2 Mike and Josie Harper Cancer Research Institute, South Bend, IN 46617, USA 3 Department of Biochemistry and Molecular Biology, Indiana University School of Medicine-South Bend, South Bend, IN 46617, USA * Correspondence: [email protected]; Tel.: +1-574-631-4002 Received: 30 September 2020; Accepted: 20 October 2020; Published: 22 October 2020 Abstract: Resistance to chemotherapy occurs through mechanisms within the epithelial tumor cells or through interactions with components of the tumor microenvironment (TME). Chemoresistance and the development of recurrent tumors are two of the leading factors of cancer-related deaths. The Adenomatous Polyposis Coli (APC) tumor suppressor is lost in many different cancers, including colorectal, breast, and prostate cancer, and its loss correlates with a decreased overall survival in cancer patients. While APC is commonly known for its role as a negative regulator of the WNT pathway, APC has numerous binding partners and functional roles. Through APC’s interactions with DNA repair proteins, DNA replication proteins, tubulin, and other components, recent evidence has shown that APC regulates the chemotherapy response in cancer cells. In this review article, we provide an overview of some of the cellular processes in which APC participates and how they impact chemoresistance through both epithelial- and TME-derived mechanisms. Keywords: adenomatous polyposis coli; chemoresistance; WNT signaling 1.
    [Show full text]
  • Teacher Background on P53 Tumor Suppressor Protein
    Cancer Lab p53 – Teacher Background on p53 Tumor Suppressor Protein Note: The Teacher Background Section is meant to provide information for the teacher about the topic and is tied very closely to the PowerPoint slide show. For greater understanding, the teacher may want to play the slide show as he/she reads the background section. For the students, the slide show can be used in its entirety or can be edited as necessary for a given class. What Is p53 and Where Is the Gene Located? While commonly known as p53, the official name of this gene is Tumor Protein p53 and its official symbol is TP53. TheTP53 gene codes for the TP53 (p53) protein which acts as a tumor suppressor and works in response to DNA damage to orchestrate the repair of damaged DNA. If the DNA cannot be repaired, the p53 protein prevents the cell from dividing and signals it to undergo apoptosis (programmed cell death). The name p53 is due to protein’s 53 kilo-Dalton molecular mass. The gene which codes for this protein is located on the short (p) arm of chromosome 17 at position 13.1 (17p13.1). The gene begins at base pair 7,571,719 and ends at base pair 7, 590,862 making it 19,143 base pairs long. (1, 2) What Does the p53 Gene Look Like When Translated Into Protein? The TP53 gene has 11 exons and a very large 10 kb intron between exons 1 and 2. In humans, exon 1 is non-coding and it has been shown that this region could form a stable stem-loop structure which binds tightly to normal p53 but not to mutant p53 proteins.
    [Show full text]
  • The NF2 Tumor Suppressor Merlin Interacts with Ras and Rasgap, Which May Modulate Ras Signaling
    Oncogene (2019) 38:6370–6381 https://doi.org/10.1038/s41388-019-0883-6 ARTICLE The NF2 tumor suppressor merlin interacts with Ras and RasGAP, which may modulate Ras signaling 1 1 2 1 1 1 Yan Cui ● Susann Groth ● Scott Troutman ● Annemarie Carlstedt ● Tobias Sperka ● Lars Björn Riecken ● 2 3 1 Joseph L. Kissil ● Hongchuan Jin ● Helen Morrison Received: 5 July 2018 / Revised: 31 March 2019 / Accepted: 1 May 2019 / Published online: 16 July 2019 © The Author(s) 2019. This article is published with open access Abstract Inactivation of the tumor suppressor NF2/merlin underlies neurofibromatosis type 2 (NF2) and some sporadic tumors. Previous studies have established that merlin mediates contact inhibition of proliferation; however, the exact mechanisms remain obscure and multiple pathways have been implicated. We have previously reported that merlin inhibits Ras and Rac activity during contact inhibition, but how merlin regulates Ras activity has remained elusive. Here we demonstrate that merlin can directly interact with both Ras and p120RasGAP (also named RasGAP). While merlin does not increase the catalytic activity of RasGAP, the interactions with Ras and RasGAP may fine-tune Ras signaling. In vivo, loss of RasGAP in 1234567890();,: 1234567890();,: Schwann cells, unlike the loss of merlin, failed to promote tumorigenic growth in an orthotopic model. Therefore, modulation of Ras signaling through RasGAP likely contributes to, but is not sufficient to account for, merlin’s tumor suppressor activity. Our study provides new insight into the mechanisms of merlin-dependent Ras regulation and may have additional implications for merlin-dependent regulation of other small GTPases. Introduction ependymomas, and astrocytomas [1].
    [Show full text]
  • Cancer Biology Introduction Proto-Oncogenes Tumor
    Introduction • Tissue homeostasis depends on the regulated cell division and self-elimination (programmed cell Cancer Biology death) of each of its constituent members except its stem cells • A tumor arises as a result of uncontrolled cell division and failure for self-elimination Chapter 18 • Alterations in three groups of genes are responsible Eric J. Hall., Amato Giaccia, for the deregulated control mechanisms that are the hallmarks of cancer cells: proto-oncogenes, tumor- Radiobiology for the Radiologist supressor genes, and DNA stability genes Proto-oncogenes Tumor-suppressor genes • Proto-oncogenes are components of signaling • Tumor-suppressor genes are also components of networks that act as positive growth the same signaling networks as proto-oncogenes, except that they act as negative growth regulators regulators in response to mitogens, cytokines, • They modulate proliferation and survival by and cell-to-cell contact antagonizing the biochemical functions of proto- • A gain-of-function mutation in only one copy oncogenes or responding to unchecked growth signals of a protooncogene results in a dominantly • In contrast to oncogenes, inactivation of both acting oncogene that often fails to respond to copies of tumor-suppressor genes is required for extracellular signals loss of function in most cases DNA stability genes Mechanisms of carcinogenesis • DNA stability genes form a class of genes • A single genetic alteration that leads to the involved in both monitoring and activation of an oncogene or loss of a tumor maintaining
    [Show full text]
  • The Functional Loss of the Retinoblastoma Tumour Suppressor
    Available online http://breast-cancer-research.com/content/10/5/R75 ResearchVol 10 No 5 article Open Access The functional loss of the retinoblastoma tumour suppressor is a common event in basal-like and luminal B breast carcinomas Jason I Herschkowitz1,2,4, Xiaping He1,2, Cheng Fan1 and Charles M Perou1,2,3 1Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27599, USA 2Department of Genetics, University of North Carolina, Chapel Hill, NC 27599, USA 3Department of Pathology & Laboratory Medicine, University of North Carolina, Chapel Hill, NC 27599, USA 4Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, DeBakey M635, Houston, TX 77030, USA Corresponding author: Charles M Perou, [email protected] Received: 19 Jun 2008 Revisions requested: 31 Jul 2008 Revisions received: 22 Aug 2008 Accepted: 9 Sep 2008 Published: 9 Sep 2008 Breast Cancer Research 2008, 10:R75 (doi:10.1186/bcr2142) This article is online at: http://breast-cancer-research.com/content/10/5/R75 © 2008 Herschkowitz et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Introduction Breast cancers can be classified using whole Results RB1 loss of heterozygosity was observed at an overall genome expression into distinct subtypes that show differences frequency of 39%, with a high frequency in basal-like (72%) and in prognosis. One of these groups, the basal-like subtype, is luminal B (62%) tumours.
    [Show full text]
  • Utimmunohistochemical Detection of the Alternate Ink4a-Encoded
    utImmunohistochemical Detection of the Alternate INK4a-Encoded Tumor Suppressor Protein p14ARF in Archival Human Cancers and Cell Lines Using Commercial Antibodies: Correlation with p16INK4a Expression Joseph Geradts, M.D., Robb E. Wilentz, M.D., Helen Roberts, B.Sc. Nuffield Department of Clinical Laboratory Sciences (JG, HR), University of Oxford, John Radcliffe Hospital, Oxford, UK; and Department of Pathology (REW), The Johns Hopkins University School of Medicine, Baltimore, Maryland KEY WORDS: Antibodies, Immunohistochemistry, The INK4a locus encodes two structurally unrelated INK4a, p14ARF, p16INK4a. tumor suppressor proteins, p16INK4a and p14ARF. Mod Pathol 2001;14(11):1162–1168 Although the former is one of the most common targets for inactivation in human neoplasia, the fre- The INK4a gene on chromosome 9p21 is one of the quency of p14ARF abrogation is not established. We most common targets for inactivation in human have developed an immunohistochemical assay neoplasia. The gene is unusual in that it encodes that allows the evaluation of p14ARF expression in two structurally unrelated proteins, p16INK4a and formalin-fixed, paraffin-embedded tissues, using p14ARF, the human homologue of murine p19ARF. commercially available antibodies. p14ARF positive Two different first exons are spliced in different cells showed nuclear/nucleolar staining, which was reading frames to common exon 2 (1). p16INK4a acts absent in all cell lines and tumors with homozygous as a retinoblastoma protein (pRB) agonist by inhib- deletions of the INK4a gene. The assay was applied iting the phosphorylation of pRB by activated to 34 paraffin-embedded cell buttons, 30 non-small cyclin-dependent kinases 4 and 6 (2). The principal INK4a cell lung cancers and 28 pancreatic carcinomas, and methods of p16 inactivation are homozygous the staining results were correlated with p16INK4a deletion of the gene, promoter methylation of exon ARF 1␣, and intragenic mutation (3).
    [Show full text]
  • Cancer Genes & Cancer Genetics
    Cancer Genes & Cancer Genetics NO office hours this Friday (5-1). Please set up an appointment if you any questions. [email protected] READING: pp. 202-220 Somatic Cells/Germ line mutations This nothing to do with + bugs Mutations passed on to progeny, all tissues, Mendelian Mutations usually little effect, cell death GERM LINE for damaged female: eggs cell; however, all cancers arise from somatic cell (precursors) mutation, one cell confined male: sperm to one tissue SOMATIC CELLS embryo proper all tissues GO STOP Cell Proliferation and Death STOP GO + Uncontrolled cell Cell division comes from suicide accumulation of (programmed cell death) genetic defects that lead to too much "go" signal, too little "stop" signal, and loss of cell suicide proliferation and programmed cell death tightly regulated to ensure the integrity of organs and tissues Checkpoint The Cell Cycle Mitosis (M-phase) STOP GO M G2 G1 S G1 G2 S STOP Checkpoint tumor suppressors (-) STOP proto-oncogenes (+) GO Checkpoints ensure the cell cycle proceeds without errors Cancer Genes Accumulation of multiple mutations Potential cancer genes - about 100 (0.3% of total) genes Inappropriate signals about need for cell division (hormonal signaling pathways: growth factors) GO Malfunctions in (CDK-cyclin) complexes controlling cell cycle transitions STOP Checkpoint breakdowns leading to DNA instability Loss of programmed cell death (cell suicide) Invasion/Metastasis Part 1: Tumor Suppressor Genes Loss-of-Function (LOF) Function no checkpoint stop; no DNA repair; STOP signal
    [Show full text]
  • The Tumor Suppressor PTEN As Molecular Switch Node Regulating Cell Metabolism and Autophagy: Implications in Immune System and Tumor Microenvironment
    cells Review The Tumor Suppressor PTEN as Molecular Switch Node Regulating Cell Metabolism and Autophagy: Implications in Immune System and Tumor Microenvironment Saveria Aquila 1,2, Marta Santoro 1,2, Annalisa Caputo 3, Maria Luisa Panno 1, Vincenzo Pezzi 1 and Francesca De Amicis 1,2,* 1 Department of Pharmacy, Health and Nutritional Sciences; University of Calabria, 87036 Rende, Italy; [email protected] (S.A.); [email protected] (M.S.); [email protected] (M.L.P.); [email protected] (V.P.) 2 Health Center, University of Calabria, 87036 Rende, Italy 3 Faculty of Medicine and Surgery, Catholic University of the Sacred Heart, 00168 Rome, Italy; [email protected] * Correspondence: [email protected] Received: 21 May 2020; Accepted: 15 July 2020; Published: 18 July 2020 Abstract: Recent studies conducted over the past 10 years evidence the intriguing role of the tumor suppressor gene Phosphatase and Tensin Homolog deleted on Chromosome 10 PTEN in the regulation of cellular energy expenditure, together with its capability to modulate proliferation and survival, thus expanding our knowledge of its physiological functions. Transgenic PTEN mice models are resistant to oncogenic transformation, present decreased adiposity and reduced cellular glucose and glutamine uptake, together with increased mitochondrial oxidative phosphorylation. These acquisitions led to a novel understanding regarding the role of PTEN to counteract cancer cell metabolic reprogramming. Particularly, PTEN drives an “anti-Warburg state” in which less glucose is taken up, but it is more efficiently directed to the mitochondrial Krebs cycle. The maintenance of cellular homeostasis together with reduction of metabolic stress are controlled by specific pathways among which autophagy, a catabolic process strictly governed by mTOR and PTEN.
    [Show full text]